<DOC>
	<DOCNO>NCT01682473</DOCNO>
	<brief_summary>To evaluate safety ( adverse event dose-limiting toxicity ) daily oral dos ZSTK474 patient advance solid malignancy .</brief_summary>
	<brief_title>A Study ZSTK474 Japanese Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description>Open-label , uncontrolled , serial cohort , dose-escalation study evaluate two different dose regimen ( Arm 1 : cycle 5 day drug 2 day drug ) , Arm 2 : cycle 21 day drug 7 day drug ) .</detailed_description>
	<criteria>Japanese male female &gt; = 20 year old Advanced ( metastatic unresectable ) solid tumor ECOG performance status score 0 1 expect survival &gt; 12 week Recovered hematological toxicity prior cancer therapy Previous treatment PI3K inhibitor Serious/significant illnesses underlying condition , include diabetes hepatic renal CV disease . Other investigational agent within previous 4 week Participating another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>PI3K inhibitor</keyword>
	<keyword>clinical trial</keyword>
</DOC>